Suppr超能文献

需要多少次抗生素暴露才能抑制革兰氏阴性菌的耐药性出现?一项系统性综述。

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

机构信息

Centre for Translational Anti-Infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.

School of Medicine, Griffith University, Gold Coast, QLD, Australia.

出版信息

Clin Pharmacokinet. 2019 Nov;58(11):1407-1443. doi: 10.1007/s40262-019-00791-z.

Abstract

BACKGROUND

The rates of antibiotic resistance in Gram-negative bacteria are increasing. One method to minimize resistance emergence may be optimization of antibiotic dosing regimens to achieve drug exposure that suppress the emergence of resistance.

OBJECTIVE

The aim of this systematic review was to describe the antibiotic exposures associated with suppression of the emergence of resistance for Gram-negative bacteria.

METHODS

We conducted a search of four electronic databases. Articles were included if the antibiotic exposure required to suppress the emergence of resistance in a Gram-negative bacterial isolate was described. Among studies, 57 preclinical studies (in vitro and in vivo) and 2 clinical studies 59 included investigated the monotherapy of antibiotics against susceptible and/or intermediate Gram-negative bacteria.

RESULTS

The pharmacokinetic/pharmacodynamic (PK/PD) indices reported to suppress the emergence of antibiotic resistance for various classes were β-lactam antibiotic minimum concentration to minimum inhibitory concentration (C/MIC) ≥ 4; aminoglycoside maximum concentration to MIC (C/MIC) ratio ≥ 20; fluoroquinolones, area under the concentration-time curve from 0 to 24 h to mutant prevention concentration (AUC/MPC) ≥ 35; tetracyclines, AUC to MIC (AUC/MIC) ratio ≥ 50; polymyxin B, AUC/MIC ≥ 808; and fosfomycin, AUC/MIC ≥ 3136. However, the exposures required to suppress the emergence of resistance varied depending on the specific antibiotic tested, the duration of the experiment, the bacterial species and the specific bacterial isolate tested. Importantly, antibiotic exposures required to suppress the emergence of resistance generally exceeded that associated with clinical efficacy.

CONCLUSION

The benefits of implementing such high PK/PD targets must be balanced with the potential risks of antibiotic-associated toxicity.

摘要

背景

革兰氏阴性菌的抗生素耐药率正在上升。减少耐药性产生的一种方法可能是优化抗生素剂量方案,以实现抑制耐药性出现的药物暴露。

目的

本系统评价的目的是描述与革兰氏阴性菌耐药性抑制相关的抗生素暴露情况。

方法

我们对四个电子数据库进行了检索。如果描述了抑制革兰氏阴性细菌分离株耐药性出现所需的抗生素暴露,则纳入研究。在研究中,57 项临床前研究(体外和体内)和 2 项临床研究研究了抗生素对敏感和/或中间革兰氏阴性细菌的单药治疗。

结果

据报道,各种类别的抗生素抑制耐药性出现所需的药代动力学/药效学(PK/PD)指标为β-内酰胺类抗生素最小浓度与最小抑菌浓度(C/MIC)比值≥4;氨基糖苷类药物最大浓度与 MIC(C/MIC)比值≥20;氟喹诺酮类药物,浓度时间曲线下面积 0 至 24 小时至突变预防浓度(AUC/MPC)比值≥35;四环素类药物,AUC 与 MIC(AUC/MIC)比值≥50;多粘菌素 B,AUC/MIC≥808;磷霉素,AUC/MIC≥3136。然而,抑制耐药性出现所需的暴露量取决于具体的抗生素、实验的持续时间、细菌种类和具体的细菌分离株。重要的是,抑制耐药性出现所需的抗生素暴露量通常超过与临床疗效相关的暴露量。

结论

实施此类高 PK/PD 目标的益处必须与抗生素相关毒性的潜在风险相平衡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验